Hearing concluded · July 23-24, 2026
The PCAC Hearing: Here's What Happened
The FDA's Pharmacy Compounding Advisory Committee voted yes on six of the seven peptides it reviewed, advancing them into formal rule-making. That is the pathway toward legally compounded peptide therapies in the United States, and away from the untested gray market.
6 of 7Yes votes
The committee voted in favor of six of the seven peptides under review.
Next stepFormal rule-making
Those peptides now enter the FDA process that can make legal U.S. compounding a reality.
Not yetFDA approval
This is a recommendation, not a final rule. It is the critical first step.
Watch the full recordings below.
Press briefing · Replay
Watch the Pre-Hearing Press Briefing
Recorded July 20, 2026, ahead of the FDA's July 23-24 PCAC hearing.
Have a press question? press@pepmed.orgFDA hearing · Day 1 · July 23
Watch the Hearing: Day 1
Full recording of Day 1 of the FDA's July 23-24, 2026 PCAC peptide hearing.
FDA hearing · Day 2 · July 24
Watch the Hearing: Day 2
Full recording of Day 2 of the FDA's July 23-24, 2026 PCAC peptide hearing.